X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (924) 924
Book Review (156) 156
Publication (60) 60
Newsletter (57) 57
Magazine Article (21) 21
Newspaper Article (19) 19
Conference Proceeding (6) 6
Trade Publication Article (6) 6
Book Chapter (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (704) 704
simvastatin (699) 699
humans (664) 664
male (362) 362
female (333) 333
statins (301) 301
middle aged (286) 286
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (253) 253
cholesterol (230) 230
aged (228) 228
simvastatin - therapeutic use (223) 223
pharmacology & pharmacy (204) 204
cost-benefit analysis (179) 179
risk factors (173) 173
atorvastatin (171) 171
simvastatin - economics (168) 168
pravastatin (167) 167
hydroxymethylglutaryl-coa reductase inhibitors - economics (164) 164
adult (162) 162
prevention (150) 150
anticholesteremic agents - therapeutic use (148) 148
antilipemic agents (148) 148
medicine, general & internal (145) 145
coronary-heart-disease (142) 142
abridged index medicus (127) 127
cardiac & cardiovascular systems (126) 126
hypercholesterolemia - drug therapy (124) 124
hypercholesterolemia (121) 121
anticholesteremic agents - economics (114) 114
cholesterol, ldl - blood (112) 112
cardiovascular diseases - prevention & control (111) 111
cardiovascular disease (109) 109
treatment outcome (107) 107
atorvastatin calcium (106) 106
drug therapy (105) 105
mortality (103) 103
simvastatin - administration & dosage (102) 102
analysis (100) 100
risk (98) 98
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (97) 97
research (96) 96
drug costs (93) 93
cost-effectiveness (88) 88
drugs (85) 85
myocardial-infarction (81) 81
cardiovascular diseases (80) 80
animals (78) 78
lipids (78) 78
therapy (78) 78
secondary prevention (76) 76
heptanoic acids - therapeutic use (75) 75
pyrroles - therapeutic use (75) 75
cardiovascular-disease (73) 73
medicine & public health (72) 72
aged, 80 and over (71) 71
efficacy (69) 69
hypolipidemic agents - therapeutic use (69) 69
lovastatin (69) 69
retrospective studies (69) 69
cardiovascular agents (68) 68
primary prevention (66) 66
ezetimibe (65) 65
health care sciences & services (64) 64
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (62) 62
heptanoic acids - economics (61) 61
internal medicine (61) 61
lovastatin - therapeutic use (61) 61
metaanalysis (61) 61
pyrroles - economics (61) 61
coronary disease - prevention & control (60) 60
rosuvastatin (60) 60
disease (59) 59
hyperlipidemias - drug therapy (58) 58
safety (58) 58
drug therapy, combination (57) 57
health aspects (57) 57
low density lipoproteins (57) 57
diabetes (56) 56
events (56) 56
pharmaceutical industry (56) 56
cholesterol - blood (55) 55
clinical trials (54) 54
care and treatment (53) 53
coronary heart disease (53) 53
medical research (53) 53
heart-disease (52) 52
studies (52) 52
cardiology (51) 51
scandinavian simvastatin survival (51) 51
coa reductase inhibitors (50) 50
medicine (50) 50
hypercholesterolemia - economics (49) 49
statin (49) 49
pravastatin - therapeutic use (48) 48
time factors (48) 48
follow-up studies (47) 47
randomized controlled trials as topic (47) 47
simvastatin - pharmacology (47) 47
dosage and administration (46) 46
simvastatin - adverse effects (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (977) 977
German (9) 9
Spanish (9) 9
Swedish (7) 7
Russian (6) 6
Dutch (4) 4
Norwegian (4) 4
Danish (3) 3
French (2) 2
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Heart, ISSN 1355-6037, 04/2017, Volume 103, Issue 7, pp. 483 - 499
ObjectiveThere is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower... 
DERIVATION | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | STATIN THERAPY | DRUGS | VALIDATION | PEOPLE | BENEFITS | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - therapeutic use | Dyslipidemias - complications | Tablets | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Simvastatin - economics | Models, Economic | Time Factors | Computer Simulation | Adult | Female | Dyslipidemias - economics | Hypertension - diagnosis | Hypertension - economics | Dyslipidemias - diagnosis | Antihypertensive Agents - economics | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - economics | Losartan - economics | Quality-Adjusted Life Years | Cardiovascular Diseases - etiology | Dyslipidemias - drug therapy | Primary Prevention - economics | Risk Assessment | Administration, Oral | Risk Factors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hydrochlorothiazide - economics | Amlodipine - therapeutic use | Cost-Benefit Analysis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Losartan - therapeutic use | Primary Prevention - methods | Hypertension - complications | Aged | Amlodipine - economics | Hydrochlorothiazide - therapeutic use | Drug Combinations | Prevention | Cardiovascular diseases | Risk assessment | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 6/2012, Volume 19, Issue 3, pp. 474 - 483
Background: While evidence shows high-dose statins reduce cardiovascular events compared with moderate doses in individuals with acute coronary syndrome (ACS),... 
cost-effectiveness | economic evaluation | statin | Acute coronary syndrome | RANDOMIZED CONTROLLED-TRIALS | POPULATION | REGISTER | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ATORVASTATIN | STATIN THERAPY | DISEASE | SIMVASTATIN | ROSUVASTATIN | BENEFITS | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Markov Chains | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Drugs, Generic - economics | Fluorobenzenes - economics | Simvastatin - economics | Fluorobenzenes - administration & dosage | Models, Economic | Quality Indicators, Health Care - economics | Clinical Trials, Phase III as Topic | Drug Prescriptions - economics | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - economics | Cardiovascular Diseases - economics | Quality-Adjusted Life Years | Heptanoic Acids - economics | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Drugs, Generic - administration & dosage | Rosuvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Treatment Outcome | Pyrimidines - economics | Randomized Controlled Trials as Topic | Atorvastatin Calcium | Medication Adherence | Secondary Prevention - economics | Cost-Benefit Analysis | Sulfonamides - economics | Bayes Theorem | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Arquivos Brasileiros de Cardiologia, ISSN 0066-782X, 2015, Volume 104, Issue 1, pp. 32 - 43
Background: Statins have proven efficacy in the reduction of cardiovascular events, but the financial impact of its widespread use can be substantial.... 
Cost-benefit analysis | Prevention | Hydroxymethylglutaryl-CoA reductase inhibitors | Unified health system | Cardiovascular diseases | Cardiovascular Diseases | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | RISK | ATORVASTATIN | Unified Health System | THERAPY | OLDER PATIENTS | Cost-Benefit Analysis | CARDIOVASCULAR-DISEASE | PRAVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors | CORONARY-HEART-DISEASE | ROSUVASTATIN | ARTERY-DISEASE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Fluorobenzenes - economics | Male | Simvastatin - economics | Fluorobenzenes - administration & dosage | Models, Economic | Pyrroles - administration & dosage | Aged, 80 and over | Brazil | Heptanoic Acids - administration & dosage | Female | Pyrroles - economics | Cardiovascular Diseases - economics | Heptanoic Acids - economics | Primary Prevention - economics | Risk Assessment | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | National Health Programs - economics | Risk Factors | Rosuvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Pyrimidines - economics | Atorvastatin Calcium | Secondary Prevention - economics | Sulfonamides - economics | Aged | Sulfonamides - administration & dosage | Original | Redutases | Doenças Cardiovasculares | Prevenção | Sistema Único de Saúde | Inibidores da Hidroximetilglutaril-Co | Análise de Custo-Benefício
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 03/2008, Volume 62, Issue 3, pp. 480 - 484
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 01/2007, Volume 61, Issue 1, pp. 15 - 23
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 2009, Volume 63, Issue 9, pp. 1320 - 1326
Aims: This study was designed to analyse the association between adherence to guidelines for rational drug use and surrogate outcome markers for hypertension,... 
MEDICINE, GENERAL & INTERNAL | RANDOMIZED-TRIALS | SWITCHING PATIENTS | INDICATORS | HIGH-RISK | GENERAL-PRACTICE | CANDESARTAN | SIMVASTATIN | PRIMARY-HEALTH-CARE | CLINICAL-OUTCOMES | ATORVASTATIN | Simvastatin - therapeutic use | Hypoglycemic Agents - economics | Humans | Hypertension - drug therapy | Simvastatin - economics | Hypercholesterolemia - drug therapy | Angiotensin-Converting Enzyme Inhibitors - economics | Cost Savings | Sweden | Diabetes Mellitus - economics | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Hypertension - economics | Antihypertensive Agents - economics | Hypoglycemic Agents - therapeutic use | Cross-Sectional Studies | Anticholesteremic Agents - economics | Diabetes Mellitus - drug therapy | Hypercholesterolemia - economics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | Antihypertensive Agents - therapeutic use | Health Expenditures | Anticholesteremic Agents - therapeutic use | Guideline Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Primary Health Care - economics | Quality of Health Care | Practice Guidelines as Topic | Hypertension | Care and treatment | Simvastatin | Glycosylated hemoglobin | Peptide hormones | Patients | Hypercholesterolemia | Pharmacy | Angiotensin converting enzyme | Angiotensin | Medical care | Hypoglycemic agents | Diabetes | Quality management | Health care expenditures | Drug therapy | Primary care | ACE inhibitors | Quality of care | Statins | Index Medicus
Journal Article
Heart, ISSN 1355-6037, 07/2011, Volume 97, Issue 14, pp. 1175 - 1181
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 6/2012, Volume 13, Issue 3, pp. 365 - 374
Coronary heart disease (CHD) remains the leading cause of death in Germany despite statin use to reduce low-density lipoprotein cholesterol (LDL-C) levels;... 
Maintenance costs | Sensitivity analysis | Secondary prevention | Lipids | Triglycerides | Diabetes | Dosage | Cholesterols | Coronary artery disease | Congenital heart defects | Economic Policy | Laropiprant | Statistics for Life Sciences, Medicine, Health Sciences | Simvastatin | Health Informatics | I10 | Public Health/Gesundheitswesen | Medicine & Public Health | Statistics for Business/Economics/Mathematical Finance/Insurance | Public Finance & Economics | Dyslipidaemia | Extended-release niacin | Hypercholesterolaemia | Cost-effectiveness | NICOTINIC-ACID | DENSITY-LIPOPROTEIN CHOLESTEROL | STATIN THERAPY | PRIMARY HYPERCHOLESTEROLEMIA | CARDIOVASCULAR-DISEASE | HEALTH POLICY & SERVICES | HDL CHOLESTEROL | ECONOMICS | CORONARY-HEART-DISEASE | CLINICAL-PRACTICE | LONG-TERM BENEFIT | NIACIN | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Simvastatin - economics | Models, Economic | Indoles - administration & dosage | Niacin - administration & dosage | Niacin - therapeutic use | Life Expectancy | Aged, 80 and over | Female | Indoles - economics | Dyslipidemias - economics | Dyslipidemias - drug therapy | Risk Assessment | Simvastatin - administration & dosage | Anticholesteremic Agents - economics | Niacin - economics | Drug Therapy, Combination - economics | Health Care Costs | Hypolipidemic Agents - economics | Anticholesteremic Agents - therapeutic use | Secondary Prevention - economics | Anticholesteremic Agents - administration & dosage | Cost-Benefit Analysis | Hypolipidemic Agents - administration & dosage | Indoles - therapeutic use | Aged | Hypolipidemic Agents - therapeutic use | Germany | Low density lipoproteins | Coronary heart disease | Niacin | Cholesterol | Antilipemic agents | Prevention | Hypercholesterolemia | Analysis | Heart diseases | Statins | Studies | Cardiovascular disease | Mortality | Benefit cost analysis | Index Medicus | Economics | Public Health | Original Paper | Gesundheitswesen | Statistics for Business | Insurance | Mathematical Finance
Journal Article
Health Affairs, ISSN 0278-2715, 2013, Volume 32, Issue 1, pp. 155 - 164
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 7/2013, Volume 16, Issue 7, pp. 907 - 916
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 4/2010, Volume 11, Issue 2, pp. 177 - 184
Background Drug costs are increasing despite the introduction of cheaper generic drugs. The aim of the present study was to analyse the entire costs of... 
Myocardial infarction | Heart | Total costs | Prescription drugs | Hospital costs | Mortality | Angiotensin converting enzyme inhibitors | Experimentation | Cost analysis | Drug costs | Economic Policy | I18 | I00 | Public Finance & Economics | Record linkage | Public Health/Gesundheitswesen | Out-patient costs | Economics / Management Science | SURVIVAL | MANAGEMENT | RANDOMIZED TRIALS | ACUTE CORONARY SYNDROMES | CLOPIDOGREL | DISEASE | HEALTH POLICY & SERVICES | UNSTABLE ANGINA | ECONOMICS | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | SIMVASTATIN | Hospital Costs | Platelet Aggregation Inhibitors - economics | Simvastatin - therapeutic use | Myocardial Infarction - mortality | Prognosis | Age Factors | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Simvastatin - economics | Catheter Ablation - economics | Angiotensin-Converting Enzyme Inhibitors - economics | Myocardial Infarction - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Atherectomy - economics | Ticlopidine - economics | Adrenergic beta-Antagonists - economics | Adult | Female | Myocardial Infarction - economics | Registries | Medical Record Linkage | Diabetes Mellitus - mortality | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Risk Factors | Anticholesteremic Agents - economics | Proportional Hazards Models | Treatment Outcome | Coronary Artery Bypass - economics | Drug Therapy, Combination - economics | Sweden - epidemiology | Ticlopidine - analogs & derivatives | Anticholesteremic Agents - therapeutic use | Myocardial Infarction - drug therapy | Health Care Costs - statistics & numerical data | Aged | Generic drugs | Coronary artery bypass | Analysis | Simvastatin | Surgery | Diabetes | Drug therapy | Heart attack | Medical care, Cost of | Studies | Heart attacks | Health care expenditures | Health economics | Index Medicus | Public Health, Global Health, Social Medicine and Epidemiology | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 2005, Volume 365, Issue 9473, pp. 1779 - 1785
Journal Article